Penserra Capital Management’s Editas Medicine EDIT Stock Holding History

Penserra Capital Management’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-12,348	Closed	-$96K	–	1283
2023 Q3	$96K	Buy	12,348 +237	+2%	+$2.03K	﹤0.01%	898
2023 Q2	$99K	Sell	12,111 -609	-5%	-$5.3K	﹤0.01%	943
2023 Q1	$92K	Buy	12,720 +430	+3%	+$3.82K	﹤0.01%	780
2022 Q4	$109K	Sell	12,290 -3,809	-24%	-$41.8K	﹤0.01%	794
2022 Q3	$197K	Buy	16,099 +7,527	+88%	+$117K	0.01%	640
2022 Q2	$101K	Buy	8,572 +800	+10%	+$10.7K	﹤0.01%	764
2022 Q1	$147K	Buy	+7,772	New	+$144K	﹤0.01%	776
2021 Q4	–	Sell	-1,560	Closed	-$64K	–	1418
2021 Q3	$64K	Buy	1,560 +15	+1%	+$822	﹤0.01%	975
2021 Q2	$87K	Buy	1,545 +25	+2%	+$923	﹤0.01%	838
2021 Q1	$63K	Buy	1,520 +90	+6%	+$5.13K	﹤0.01%	781
2020 Q4	$100K	Buy	1,430 +898	+169%	+$36.9K	﹤0.01%	605
2020 Q3	$14K	Buy	+532	New	+$17.3K	﹤0.01%	777

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Penserra Capital Management's EDIT Position: Q4 2023 in Review

Penserra Capital Management sold out of Editas Medicine (EDIT) in Q4 2023, closing a stake of 12,348 shares — an estimated $96K sold.

Penserra Capital Management first reported a position in EDIT in Q3 2020 and held it in 12 quarters. The position peaked at $197K in Q3 2022. 225 funds tracked by Wall St. Rank hold EDIT as of Q4 2023.

Penserra Capital Management reported no remaining Editas Medicine position as of Q4 2023 after selling out during the quarter.
Penserra Capital Management sold 12,348 Editas Medicine shares in Q4 2023, an estimated $96K.
Penserra Capital Management first reported a position in Editas Medicine in Q3 2020 and held it in 12 quarters.
Penserra Capital Management's Editas Medicine position peaked at $197K in Q3 2022.
225 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2023.

Based on Penserra Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.